Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review

Timothy J. Wilt, Kristen E. Ullman, Eric J. Linskens, Roderick MacDonald, Michelle Brasure, Elizabeth Ester, Victoria A. Nelson, Jayati Saha, Shahnaz Sultan, Philipp Dahm

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE: We sought to identify new information evaluating clinically localized prostate cancer therapies. MATERIALS AND METHODS: Bibliographic databases (2013-January 2020), ClinicalTrials.gov and systematic reviews were searched for controlled studies of treatments for clinically localized prostate cancer with duration ≥5 years for mortality and metastases, and ≥1 year for harms. RESULTS: We identified 67 eligible references. Among patients with clinically, rather than prostate specific antigen, detected localized prostate cancer, watchful waiting may increase mortality and metastases but decreases urinary and erectile dysfunction vs radical prostatectomy. Comparative mortality effect may vary by tumor risk and age but not by race, health status, comorbidities or prostate specific antigen. Active monitoring probably results in little to no mortality difference in prostate specific antigen detected localized prostate cancer vs radical prostatectomy or external beam radiation plus androgen deprivation regardless of tumor risk. Metastases were slightly higher with active monitoring. Harms were greater with radical prostatectomy than active monitoring and mixed between external beam radiation plus androgen deprivation vs active monitoring. 3-Dimensional conformal radiation and androgen deprivation plus low dose rate brachytherapy provided small mortality reductions vs 3-dimensional conformal radiation and androgen deprivation but little to no difference on metastases. External beam radiation plus androgen deprivation vs external beam radiation alone may result in small mortality and metastasis reductions in higher risk disease but may increase sexual harms. Few new data exist on other treatments. CONCLUSIONS: Radical prostatectomy reduces mortality vs watchful waiting in clinically detected localized prostate cancer but causes more harms. Effectiveness may be limited to younger men and those with intermediate risk disease. Active monitoring results in little to no mortality difference vs radical prostatectomy or external beam radiation plus androgen deprivation. Few new data exist on other treatments.

Original languageEnglish (US)
Pages (from-to)967-976
Number of pages10
JournalThe Journal of urology
Volume205
Issue number4
DOIs
StatePublished - Apr 1 2021

Keywords

  • androgen antagonists
  • brachytherapy
  • male
  • prostate-specific antigen
  • prostatic neoplasms

Fingerprint Dive into the research topics of 'Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review'. Together they form a unique fingerprint.

Cite this